Kiek dividendų moka Sihuan Pharmaceutical Holdings Group 2024?
Pagal paskutinę informaciją nuo Spalis 2024, Sihuan Pharmaceutical Holdings Group per paskutinius 12 mėnesių mokėjo bendrą dividendą, kuris sudarė 0,07 CNY už akciją. Esant dabartiniam Sihuan Pharmaceutical Holdings Group kursui 0,65 CNY, tai atitinka 11,40 % dividendų grąžą.
Dividendai mokami kartus per metus.
11,40 % Dividendo grąža | = | 0,07 CNY Dividendas | 0,65 CNY akcijų kaina |
|
Ar Sihuan Pharmaceutical Holdings Group dividendai yra saugūs?
Sihuan Pharmaceutical Holdings Group kasmet didina dividendus jau 3 metus.
Per pastaruosius 10 metus Sihuan Pharmaceutical Holdings Group kasmet 3,895 % padidėjo.
Per 5 metų laikotarpį augo išmokos padidėjo 28,648 %.
Analitikai prognozuoja, kad einamaisiais verslo metais Dividendų mažinimas bus −15,402%.
Sihuan Pharmaceutical Holdings Group Aktienanalyse
Ką daro Sihuan Pharmaceutical Holdings Group?
Sihuan Pharmaceutical Holdings Group Ltd is a leading company in the Chinese pharmaceutical industry that focuses on research, development, production, and marketing of drugs, especially for the treatment of cardiovascular diseases and central nervous system diseases. The company was founded in 2001 and has become one of the largest and most successful companies in the Chinese pharmaceutical industry. It is listed on the stock exchange and has its headquarters in Beijing, China. Sihuan Pharmaceutical's business model is based on a combined strategy of researching and developing new drugs tailored to the Chinese market, as well as licensing and distributing existing drugs from both domestic and international sources. The company is divided into various business divisions to maximize its core competencies and maintain growth. The cardiovascular division is one of the most important divisions, producing and distributing cardiovascular drugs used to treat conditions such as hypertension, heart failure, arrhythmias, and other cardiovascular diseases. The central nervous system division is another important division, producing and distributing drugs to treat neurological disorders such as depression, schizophrenia, and epilepsy. In addition, the company also has products in the areas of antibiotics, antivirals, and gastroenterology. Sihuan Pharmaceutical's research and development department focuses on the discovery and development of new active substances, as well as improving existing drugs. The company collaborates with leading universities and research institutions in China and globally to develop innovative approaches in pharmacy. Sihuan Pharmaceutical has also established a strong presence in the Chinese market, building an extensive distribution network throughout China and working closely with other key players in the industry to strengthen its market position. In summary, Sihuan Pharmaceutical Holdings Group Ltd is a significant player in the Chinese pharmaceutical industry, specializing in the research, development, production, and marketing of drugs for the treatment of cardiovascular diseases and central nervous system diseases. The company is divided into multiple business divisions and has a strong presence in the Chinese market. With its strong research and development department, Sihuan Pharmaceutical is committed to improving the health and well-being of millions of people worldwide. Sihuan Pharmaceutical Holdings Group yra viena populiariausių įmonių Eulerpool.com svetainėje.Akcijų taupymo planai siūlo patrauklią galimybę investuotojams ilgalaikėje perspektyvoje kurti turtą. Vienas pagrindinių privalumų yra vadinamasis vidutinės išlaidos efektas: reguliariai investuojant fiksuotą sumą į akcijas arba akcijų fondus, automatiškai perkama daugiau dalinių vertybių popierių, kai kainos yra žemos, ir mažiau – kai jos aukštos. Tai gali lemti palankesnę vidutinę dalies kainą per laiką. Be to, akcijų taupymo planai suteikia galimybę ir smulkiesiems investuotojams patekti į brangias akcijas, nes jie gali dalyvauti jau su mažomis sumomis. Reguliarus investavimas taip pat skatina disciplinuotą investavimo strategiją ir padeda išvengti emociškai pagrįstų sprendimų, pavyzdžiui, impulsyvaus pirkimo ar pardavimo. Be to, investuotojai gauna naudos iš potencialaus akcijų vertės augimo bei iš dividendų, kurie gali būti reinvestuoti, kas sustiprina sudėtinio palūkanų efektą ir taip skatina investuoto kapitalo augimą.